← All trials
NCT02794285
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2016
- Primary completion
- Jun 14, 2021
- Completion date
- Jun 14, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 575
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- University of California, San DiegoOverall official - principal investigator
- AstraZenecaStudy director
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.